Devin. on you, doing for the Hope joining addressing forward-looking as note will Thanks slides that everybody's I'll today's us you Thank ask non today. well call. we to GAAP the you and refer statements measure always. please
begin like on So, three. I'd slide to
to exciting brief ended summary, see, record you'll with eventful year we least the what a KORU begin As Medical. for and product. strong new team was financial year in financial refreshed say a a In the on overview market, results, of our and generated the an preparing enterprise-wide and Board, to NASDAQ position, launch rebranding our initiative, management we capital developed and a listed implemented
We on two which with favorable judgments respect also to defend increased will appeal. litigation, shareholder engagement our ongoing believe consecutive we activities we and our receive
February you well as ringing and family. closing the XXth of the as associates, happy to team in Board a by bell be the will see of slide, had friends, on also York -- our management we very the day NASDAQ very As and members We're bell New members City. on joined memorable
net margin. to net last primarily due $XXX,XXX $XXX,XXX slide XXXX to annual four. Let profit, in highest-ever me gross the nearly a costs. income, sales, We transition We from generated down year full gross reported with record litigation and year,
execution. to work, million Our insights, Medical in as I XXXX to want for million thank $X.X compared record hard their EBITDA $X.X increased $X to by KORU adjusted everyone and million XXXX. nearly at initiative,
two have spent rivals that any team industry. in past, years As the putting in our a we I've the stated last together
we significantly, continued believe have a beyond. shortly. results reported XXXX, growth detail XXXX we Karen greater will for in more our you what and will in walk a be through foundation Together, record created and solid
disease In to CIDP U.S. state PIDD continue comprise us for a the and IG use the consumable a our CIDP, to and brings and and Freedom total expand. subcutaneous five and end believe Slide of PIDD total will -- needle aggregate, $XXX largest currently approximately our market markets, of sets of that therapy, SUBQ-IG tubing we primary Pumps markets addressable the million. for two
to Our establish a reflect means delivery in patients penetrating for system markets as our validate these our results success year preferred the of treatment these the for drug end and conditions. Freedom undergoing of efforts
for just patient population three a U.S. increasingly PIDD two estimate X% worldwide estimated believe of that therapy receiving estimated system. people penetration market bringing the The that XXX,XXX to PIDD, being the the SUBQ-IG for roughly times Freedom have is population, with are Of is condition we to addressable XX,XXX to PIDD represents we That PIDD estimated at diagnosed. X patients. market million the that
a we patient revenue model. each generates Medical have chronic, We the system estimate that these to Freedom recurring using revenue about average are sticky annually. Because $XXX very KORU conditions of
drugs of with of U.S. to treat clearance approved This IVIG U.S. compares PIDD. XX the market. for to drugs five SUBQ-IG the know You'll names a total
continue therapy. We therapeutic to these compared patient as advantages drugs and IV IVIG of to to will some a inherent formulation therapies cost SUBQ given SUBQ-IG of believe migrate comfort the
to the move aware with are SUBQ underway initiatives of IV supply patients are increasing to from of We that SUBQ-IG. Specialty Pharmacy
entrant Xembify treatment launched PIDD. by in XXXX the of Grifols is the for December having newest
have product in Grifols been have communication close launch. with support supplied and its to We
XXst, for as growth be in month, December ended dermatomyositis, drug. trial stronger is subcutaneous sales the majority continues CSL in method even we for the by and is six number it our enrolled overall is CSL, the growth space. in in believe Hizentra system strong Phase believe represents that patient's Hizentra delivery Hizentra a this XXXX. preferred Behring one of to could prescriptions our the system reported III Hizentra our experience to Freedom announced CSL also earlier and product revenues they for the new months According we of in very where currently utilized.
Hizentra unmet CIDP of again, XXXX, needs addresses population U.S. overall XX,XXX. with of our benefits approved treating IVIG to which CIDP and treat as of patient IV of reformulating in of In a that to to the compared align thesis overall reflects trend therapy. an the and to quality number improve was generate the Hizentra with subcutaneous life. estimated growing traditional believe extend We therapies therapy revenue, SUBQ this a of of lives, incremental patient most patients'
times CSL, than noted that many five a Hizentra the In also offers Hizentra that patients many patients felt side conducted they compared Eight levels and provides by effects Hizentra state as drug IG as patients said therapy. fewer times to as said IVIG freedom IVIG steady more with study
CIDP. designation In subcutaneous orphan of seven-year provides drug exclusivity a December, from CIDP U.S. FDA treatment CSL therapy. This Hizentra of period of also marketing the treatment maintenance for with patients received with Hizentra exclusivity the adult the in for
is dosing reminder, two times a more frequent PIDD. CIDP for for As typically three that than to
So, recurring annual per patients year -- figure the using for patient likely $XXX revenue the higher recurring be CIDP of PIDD will Freedom annual per system.
growth collections IG United demand on left Transitioning to is supply projected driving the This plasma IG on chart could SUBQ-IG the slide additional six, across the adoption. drugs accelerate shown the in States. for
has the that XX collection since is collections XXXX note source you'll more of to collections The centers than U.S. XXXX. million XXXX. year in number worldwide plasma nearly leading U.S. right, of the increased plasma the doubled and On each since plasma
X% now represents of In fact, total U.S. plasma the approximately exports.
Grifols, maker states. ongoing By We least bodes the quarter supply bolstering securing XX believe way a plasma our Medical example, the XXX growth investment a continuing that total. That's the centers of of in KORU of well and U.S. whole. at and and of as for runs collection Xembify industry in
company CSL more collection strategic currently than logistics five a plasma in manufacturers has U.S. manufacturing one is in and plasma XXX XXX Plasma industry, facilities. capacity next which than operating of stated CUVITRU of the more has the Behring CSL which Hizentra long-term XX% goal has and donor part with sites, over a and is years. the centers the testing Takeda that supply of largest HyQvia manufacturers The networks increasing by which focus. plus
The beyond view, slide that in therapy chronic beyond immune encapsulates numbers, positive the life. a condition seven, the have such of with On can our or person's It ramifications be how ability conditions of times you enjoy even a society, with slide SUBQ-IG job. extend on as far a hold a this feel. steady to effects living can productive your CIDP and friends, impact your member can PIDD and family
in that month. a here treat Dawn has days DuBois states her to condition SUBQ-IG immune given switching from extra XX pictured IVIG to her
as SUBQ-IG consistent does compared suffer not As highs therapy, IVIG at between infuse therapy. a and with are to associated side as of serum home, IVIG lows switching to can levels Dawn effects, fewer result the more treatments therapy, has
you out life around her our infuse IVIG. with has managing As to Dawn at are to Freedom ourselves We like look is these Dawn lower system she living using therapy home. help being point hand after no left of states, to if who types SUBQ-IG at I'll corner, from on conditions. able and Dawn to schedule individuals chronic now the pride longer treatment switching that
I speak markets specific delivery in become partner the drug things infusion turning Before our for therapies preferred want over as to eight. on select to slide seen Karen, to to roadmap
multiyear is of the approach, highlight to I'd a Although multi-faceted this progress. like areas
margin to each and towards million continue our a year by growth revenue manage We operating goal XX% year. our gross year organic the drive business and goal XXXX, by towards end the generate efficiencies of our $XX us rate to run improve XXXX, XX%-plus
gross sales XXX you'll and Broadly, by addressable than people. clearly see and the our combination more a growing over of by the reflects have markets, margin than and points during On strategy years three well-executed defined net has improved that XX% slide time. grown more great our this basis nine, last
as penetrating and on expand this European markets supply. increased growth both expect We these our in by with reach to we increasing and end overseas. manufacturers sales trend XX.X% pharma XXXX continue primary continue into IG markets, to their focus domestically see
reflects are IG other Clinical trials future our very focused XXXX rose in drugs. revenue trial clinical our from which clinical we on of driver and this efforts. as XXXX, supplying view We key success trial a sales in and future
higher benefited on sustained efficiency that meaningful has related a is derived manufactured initiatives from margin provide can more we sales and net volume, benefit. gross cost focusing believe from Our but the reduction
providers. improve specialty to customers, with positions pharmacies We our contractual continue key our infusion solidify and home both
suggests superior no characteristics a in the Flo This time, tolerability satisfaction. comfort, data in changes areas therapy. patient including and HIgH that announce in time a needle SuperXX to against tool SuperXX products, Flo study SuperXX Flo On happy commencing the this our year. new safety XX very launch slide I'm demonstrated XX, gauge respect subcutaneous standard HIgH our tolerability, of the patients patient and to replacement in of may requiring with HIgH improve infusion QX decrease needle valuable fusion be overall set, with experience head-to-head set to subcutaneous In
launch impact Although we the on have results this to excited product with in our long-term of expansion the experience. XXXX, positively are not we a forecasting very significant our of that line feel enhance prospects will the are SuperXX patient we
As out initiatives and with user a infusion XXXX, development margins. expenditures expansion goal our focused reflected in increased more of gross developing applications products and our results, R&D our problems, XXXX team. commercializing of reflecting new than the current and and experience, three-fold impacting product improving positively from our the on we building our We're infusion solving
On companies as on strategic component and important model focus plan. a support can relationship that this slide XX, our to CSL to developing providing like continue we for of product consider pharmaceutical
do impact and early SUBQ-IG increasing and CUTAQUIG such Xembify KORU to we of positive it's for quantify increase to and quantify Although detail supply. any will -- awareness our the patient physician new results, growth incremental drugs too or in as drug through produce believe in Medical sales
in in of therapies area a launch. clinical involved and potential the efficacy Phase with endpoint associated its with hematology met defined or III be Freedom completed Our for of currently other days. multiple is recently This IG to that primary development subcutaneous expansion disease trials yet SUBQ of system other drug includes the
continue to actively We pursue these opportunities.
will results. Fisher, I'll now our to who CFO, Karen you our through walk over things turn
